• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发伊朗医疗保险福利优化模型——IR-HIBOM:一种用于设计基本医疗保险福利套餐的具有决策规则的多标准决策分析。

Developing the Iranian health insurance benefit optimization model - the IR-HIBOM: a multicriteria decision analysis with decision rules for designing basic health insurance benefit packages.

作者信息

Darvishi Ali, Akbari Sari Ali, Yaseri Mehdi, Mobinizadeh Mohammadreza, Daroudi Rajabali

机构信息

Department of Health Policy and Management, School of Public Health and Safety, https://ror.org/034m2b326Shahid Beheshti University of Medical Sciences, Tehran, Iran.

National Center for Health Insurance Research, Tehran, Iran.

出版信息

Int J Technol Assess Health Care. 2025 Jul 21;41(1):e50. doi: 10.1017/S0266462325100263.

DOI:10.1017/S0266462325100263
PMID:40685607
Abstract

OBJECTIVES

Prioritization of health technologies for insurance coverage is usually based on explicit and implicit criteria. This study presents the development of the multi-criteria decision analysis (MCDA) model, the Iranian Health Insurance Benefit Optimization Model (IR-HIBOM), to inform the design of basic health insurance benefit packages.

METHODS

An initial set of twenty-nine potential allocation criteria was identified through a review of available evidence and other relevant literature. Review of this set by three specialized panels yielded a final set of thirteen criteria. A cross-sectional survey using the best-worst scaling method was then fielded to 163 health system experts to evaluate their preferences regarding the relative importance of the allocation criteria. The mixed logit method was employed to determine the weight of the relative importance of each criterion. Subsequently, a multilevel criteria scoring framework was defined based on a review of similar models and input from a panel of five expert members of the study team. Finally, model's appraisal was conducted.

RESULTS

Thirteen criteria, including relative safety, efficacy, disease severity, access to alternative health technologies, budget impacts, cost-effectiveness, quality of evidence, population size, age, job absenteeism, economic status, daily care needs, and ease-of-use/acceptance were selected. Cost-effectiveness and ease-of-use criteria had the highest and lowest relative importance weights, with 30.5 percent and 1 percent, respectively. Furthermore, scores were determined for the several levels of each criterion, and decision rules were defined for the cost-effectiveness and budget impact criteria. The final model's appraisal, based on weighted scores of thirteen selected technologies, indicated that it was valid and applicable.

CONCLUSIONS

The IR-HIBOM demonstrated its potential utility in the health resource allocation.

摘要

目标

医保覆盖范围内卫生技术的优先排序通常基于明确和隐含的标准。本研究介绍了多标准决策分析(MCDA)模型——伊朗健康保险福利优化模型(IR-HIBOM)的开发过程,以指导基本健康保险福利包的设计。

方法

通过回顾现有证据和其他相关文献,确定了一组初步的29个潜在分配标准。由三个专业小组对这组标准进行审查后,得出了最终的13个标准。然后,采用最佳-最差尺度法对163名卫生系统专家进行横断面调查,以评估他们对分配标准相对重要性的偏好。采用混合逻辑回归方法确定每个标准相对重要性的权重。随后,在回顾类似模型并参考研究团队五名专家成员小组的意见后,定义了一个多层次标准评分框架。最后对模型进行了评估。

结果

选择了13个标准,包括相对安全性、有效性、疾病严重程度、获得替代卫生技术的机会、预算影响、成本效益、证据质量、人口规模、年龄、旷工、经济状况、日常护理需求以及易用性/可接受性。成本效益标准和易用性标准分别具有最高和最低的相对重要性权重,分别为30.5%和1%。此外,还确定了每个标准几个级别的得分,并为成本效益和预算影响标准定义了决策规则。基于13种选定技术的加权得分对最终模型进行评估,结果表明该模型有效且适用。

结论

IR-HIBOM在卫生资源分配中显示出其潜在效用。

相似文献

1
Developing the Iranian health insurance benefit optimization model - the IR-HIBOM: a multicriteria decision analysis with decision rules for designing basic health insurance benefit packages.开发伊朗医疗保险福利优化模型——IR-HIBOM:一种用于设计基本医疗保险福利套餐的具有决策规则的多标准决策分析。
Int J Technol Assess Health Care. 2025 Jul 21;41(1):e50. doi: 10.1017/S0266462325100263.
2
Review of guidelines for good practice in decision-analytic modelling in health technology assessment.卫生技术评估中决策分析模型良好实践指南综述。
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. doi: 10.3310/hta8360.
3
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
4
Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation.成人和儿童轻微头部损伤的诊断管理策略:系统评价和经济评估。
Health Technol Assess. 2011 Aug;15(27):1-202. doi: 10.3310/hta15270.
5
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
6
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
7
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
Digital interventions in mental health: evidence syntheses and economic modelling.数字干预在精神健康中的应用:证据综合和经济建模。
Health Technol Assess. 2022 Jan;26(1):1-182. doi: 10.3310/RCTI6942.
10
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.

本文引用的文献

1
Public preferences regarding the priority setting criteria of health interventions for budget allocation: results of a survey of Iranian adults.公众对健康干预措施预算分配的优先顺序设定标准的偏好:对伊朗成年人调查的结果。
BMC Public Health. 2022 Nov 8;22(1):2038. doi: 10.1186/s12889-022-14404-1.
2
Topic selection for health technology assessment: An approach combining multiple attribute decision making and decision rules.卫生技术评估的主题选择:一种结合多属性决策和决策规则的方法。
Med J Islam Repub Iran. 2021 Mar 27;35:40. doi: 10.47176/mjiri.35.40. eCollection 2021.
3
History of Health Technology Assessment in Iran.
伊朗卫生技术评估的历史。
Int J Technol Assess Health Care. 2020;36(1):34-39. doi: 10.1017/S0266462319003489. Epub 2020 Jan 13.
4
Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.多准则决策分析支持卫生技术评估机构:收益、限制和未来发展方向。
Value Health. 2019 Nov;22(11):1283-1288. doi: 10.1016/j.jval.2019.06.014. Epub 2019 Oct 16.
5
So Near, So Far: Four Decades of Health Policy Reforms in Iran, Achievements and Challenges.近在咫尺,远在天涯:伊朗四十年卫生政策改革,成就与挑战并存。
Arch Iran Med. 2019 Oct 1;22(10):592-605.
6
A model for priority setting of health technology assessment: the experience of AHP-TOPSIS combination approach.一种卫生技术评估优先级设定模型:层次分析法-理想解排序法组合方法的经验
Daru. 2016 Apr 11;24:10. doi: 10.1186/s40199-016-0148-7.
7
A model for HTA priority setting: experience in Lithuania.卫生技术评估优先事项设定模型:立陶宛的经验
Int J Technol Assess Health Care. 2013 Oct;29(4):450-5. doi: 10.1017/S0266462313000470.
8
Mapping of multiple criteria for priority setting of health interventions: an aid for decision makers.多标准健康干预措施优先级设定图:决策者的辅助工具。
BMC Health Serv Res. 2012 Dec 13;12:454. doi: 10.1186/1472-6963-12-454.
9
Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions.在医疗保健决策中使用每获得一个质量调整生命年的成本阈值。
Int J Technol Assess Health Care. 2011 Jan;27(1):71-6. doi: 10.1017/S0266462310001194. Epub 2011 Jan 25.
10
Valuing citizen and patient preferences in health: recent developments in three types of best-worst scaling.重视公民和患者的健康偏好:三种类型最佳最差量表法的最新进展。
Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):259-67. doi: 10.1586/erp.10.29.